Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Portola Pharmaceuticals Inc
Portola Pharmaceuticals Inc
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Manufacturing
Lonza starts commercial supply of Portola’s second-gen coagulant
The FDA Prior Approval Supplement has been authorised and second-gen Andexxa will be produced on a large scale
Regulatory
Antiplatelet therapy – elinogrel
Clopidogrel is a mainstay of the treatment of cardiovascular disease, but resistance, variable response and irreversibility can cause problems
Regulatory
Novartis acquires rights to anti-clotting drug
<p>Novartis, the Swiss pharma company, has acquired the worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack and stroke.</p>
Subscribe now